ES2575666T3 - Proceso de fabricación de un agente farmacéuticamente activo - Google Patents

Proceso de fabricación de un agente farmacéuticamente activo Download PDF

Info

Publication number
ES2575666T3
ES2575666T3 ES10803222.8T ES10803222T ES2575666T3 ES 2575666 T3 ES2575666 T3 ES 2575666T3 ES 10803222 T ES10803222 T ES 10803222T ES 2575666 T3 ES2575666 T3 ES 2575666T3
Authority
ES
Spain
Prior art keywords
manufacturing process
active agent
pharmaceutically active
formula
hydrogenate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10803222.8T
Other languages
English (en)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of ES2575666T3 publication Critical patent/ES2575666T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Un procedimiento para la preparación del compuesto de fórmula IV,**Fórmula** Fórmula IV que comprende las etapas de: (a) mezclar (6-fluoro-1H-indol-3-il)acetonitrilo, NH3 en agua y un catalizador de metal de transición en un disolvente alcohólico; y (b) hidrogenar la mezcla con H2.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES10803222.8T 2009-12-23 2010-12-20 Proceso de fabricación de un agente farmacéuticamente activo Active ES2575666T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
US289530P 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent

Publications (1)

Publication Number Publication Date
ES2575666T3 true ES2575666T3 (es) 2016-06-30

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10803222.8T Active ES2575666T3 (es) 2009-12-23 2010-12-20 Proceso de fabricación de un agente farmacéuticamente activo

Country Status (37)

Country Link
US (3) US8461353B2 (es)
EP (1) EP2516394B1 (es)
JP (2) JP5864435B2 (es)
KR (2) KR101796330B1 (es)
CN (2) CN103694161B (es)
AR (1) AR079580A1 (es)
AU (1) AU2010335659B2 (es)
BR (1) BR112012015749A2 (es)
CA (1) CA2785440C (es)
CL (1) CL2012001725A1 (es)
CR (1) CR20120316A (es)
CY (1) CY1118032T1 (es)
DK (1) DK2516394T3 (es)
DO (1) DOP2012000170A (es)
EA (1) EA021440B1 (es)
ES (1) ES2575666T3 (es)
GE (1) GEP20146078B (es)
HR (1) HRP20160518T1 (es)
HU (1) HUE028806T2 (es)
IL (2) IL220329A (es)
MA (1) MA33945B1 (es)
ME (1) ME02401B (es)
MX (1) MX2012007078A (es)
MY (1) MY159251A (es)
NZ (2) NZ600639A (es)
PH (1) PH12012501258A1 (es)
PL (1) PL2516394T3 (es)
PT (1) PT2516394E (es)
RS (1) RS54820B1 (es)
SG (1) SG181910A1 (es)
SI (1) SI2516394T1 (es)
SM (1) SMT201600166B (es)
TN (1) TN2012000279A1 (es)
TW (1) TW201139370A (es)
UA (1) UA111584C2 (es)
WO (1) WO2011076212A2 (es)
ZA (1) ZA201305936B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
US9975850B2 (en) * 2016-04-08 2018-05-22 H. Lundbeck A/S Process for the manufacture of idalopirdine via hydrogenation of an imine
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist
US12275709B2 (en) * 2018-12-27 2025-04-15 Hoffmann-La Roche Inc. Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
JP2851439B2 (ja) 1993-12-28 1999-01-27 ローヌープーラン シミ ニトリルを水素化してアミンにするための触媒の調製方法及びこの触媒の水素化における用途
DE69416697T2 (de) 1993-12-28 1999-09-09 Rhodia Fiber & Resin Intermediates Verfahren zur katalytischer hydrogenierung von nitrilen zu aminen in anwesenheit eines dosierten raney nickel katalysators
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
JP2001508197A (ja) 1997-10-31 2001-06-19 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 構成信号にノイズを加算してｌｐｃ原理により符号化された音声のオーディオ再生のための方法及び装置
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
SI1859798T1 (sl) * 2001-03-29 2016-07-29 Eli Lilly And Company N-(2-ariletil) benzil amini kot antagonisti 5-ht6 receptorja
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
CA2633243C (en) 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
CR20120316A (es) 2012-08-16
MY159251A (en) 2016-12-30
KR101796330B1 (ko) 2017-11-09
HK1196352A1 (en) 2014-12-12
KR101873182B1 (ko) 2018-06-29
CN103694161A (zh) 2014-04-02
DK2516394T3 (en) 2016-06-13
IL220329A0 (en) 2012-08-30
NZ625798A (en) 2014-10-31
KR20170125417A (ko) 2017-11-14
AR079580A1 (es) 2012-02-01
UA111584C2 (uk) 2016-05-25
EP2516394A2 (en) 2012-10-31
ME02401B (me) 2016-09-20
CA2785440A1 (en) 2011-06-30
SI2516394T1 (sl) 2016-07-29
AU2010335659A1 (en) 2012-07-05
TW201139370A (en) 2011-11-16
CN102656146B (zh) 2014-12-17
HUE028806T2 (en) 2017-01-30
JP5864435B2 (ja) 2016-02-17
PH12012501258A1 (en) 2013-02-04
EP2516394B1 (en) 2016-03-16
RS54820B1 (sr) 2016-10-31
CN103694161B (zh) 2015-09-09
MA33945B1 (fr) 2013-01-02
WO2011076212A3 (en) 2011-08-11
DOP2012000170A (es) 2012-08-31
WO2011076212A2 (en) 2011-06-30
CA2785440C (en) 2018-05-01
NZ600639A (en) 2014-07-25
US9382205B2 (en) 2016-07-05
CY1118032T1 (el) 2017-05-17
US20150080584A1 (en) 2015-03-19
EA201290552A1 (ru) 2012-12-28
MX2012007078A (es) 2012-07-20
KR20120112480A (ko) 2012-10-11
PT2516394E (pt) 2016-06-07
HK1174921A1 (en) 2013-06-21
IL231141A (en) 2016-03-31
US20110152539A1 (en) 2011-06-23
CN102656146A (zh) 2012-09-05
IL231141A0 (en) 2014-03-31
TN2012000279A1 (en) 2013-12-12
SMT201600166B (it) 2016-07-01
IL220329A (en) 2016-03-31
GEP20146078B (en) 2014-04-10
JP2013515683A (ja) 2013-05-09
SG181910A1 (en) 2012-08-30
AU2010335659B2 (en) 2015-05-21
US8461353B2 (en) 2013-06-11
PL2516394T3 (pl) 2016-09-30
BR112012015749A2 (pt) 2015-09-15
US20130245281A1 (en) 2013-09-19
HRP20160518T1 (hr) 2016-06-03
ZA201305936B (en) 2015-09-30
US8901318B2 (en) 2014-12-02
CL2012001725A1 (es) 2012-11-30
JP2016117734A (ja) 2016-06-30
EA021440B1 (ru) 2015-06-30
JP6195605B2 (ja) 2017-09-13

Similar Documents

Publication Publication Date Title
CL2012001725A1 (es) Procesos para la preparacion de 2-(6-fluoro-1h-indol-3-il)etanamina, a partir de (6-fluoro-1h-indol-3-il)acetonitrilo y un catalizador de metal de transicion en un solvente alcoholico, posteriormente hidrogenar la mezcla con h2.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
ES2542780T3 (es) Agente acelerante para curar resinas
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
AR062059A1 (es) Espuma farmaceutica con acido graso
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
CO6341578A2 (es) Síntesis de estirilpiridinas radiomarcadas con 18f a partir de precursores de tosilato y composiciones farmacéuticas estables de estas
PE20142371A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
MX2019012598A (es) Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
GB2481775A (en) Thinning agent
CL2012000374A1 (es) Metodo para la preparacion de una composicion saborizante activa que comprende una primera reaccion entre un compuesto amino y un carbonilo, resultando una primera mezcla de intermediarios, una segunda reaccion con un segundo compuesto amino solo o en combinacion con un compuesto carbinilo, resultando una segunda mezcla de intermediarios, reacciones serparadas adicionales con compuestos de otras clases quimicas, ultima reaccion que comprende una mezcla de todas las mezclas de intermediarios anteriores.
ES2555778T3 (es) Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos
ES2542733B1 (es) Brazo de Soporte para reflector conformado
BR112012014621A2 (pt) processo para a preparação de compostos de quelato
TR201904884T4 (tr) Koloni̇k boşaltmada kullanima yöneli̇k formülasyonlar ve formülasyonlarin üreti̇m yöntemleri̇
AR085349A1 (es) Metodo para preparar un precursor de catalizador y proceso de sintesis de hidrocarburos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ECSP077263A (es)
AR081732A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
BR112012005938A2 (pt) formas de dosagem, e, processo para produzir preparações para formas de dosagem de ingredientes ativos de baixa solubilidade em água
AR067534A1 (es) Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
RU2008105019A (ru) N-замещенные 4-метил-2,6-дихлорникотиноил-мочевины в качестве антидотов 2,4-д на подсолнечнике